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Introduction: Human papillomavirus 16 (HPV16) is the main cause of oropharyngeal
squamous cell carcinoma (OPSCC). To date, the links between HPV16 gene expression
and adaptive immune responses have not been investigated. We evaluated the
correlation of HPV16 DNA, RNA transcripts and features of adaptive immune
response by evaluating antibody isotypes against E2, E7 antigens and density of
tumor-infiltrating lymphocytes (TIL).
Material and Methods: FFPE-tissue from 27/77 p16-positive OPSCC patients was
available. DNA and RNA were extracted and quantified using qPCR for all HPV16 genes.
The TIL status was assessed. Immune responses against E2 and E7 were quantified by
ELISA (IgG, IgA, and IgM; 77 serum samples pre-treatment, 36 matched post-treatment).
Results: Amounts of HPV16 genes were highly correlated at DNA and RNA levels. RNA
co-expression of all genes was detected in 37% (7/19). E7 qPCR results were
correlated with higher anti-E7 antibody (IgG, IgA) level in the blood. Patients with
high anti-E2 IgG antibody (>median) had better overall survival (p=0.0311); anti-E2 and
anti-E7 IgA levels had no detectable effect. During the first 6 months after treatment, IgA
but not IgG increased significantly, and >6 months both antibody classes declined over
time. Patients with immune cell-rich tumors had higher levels of circulating antibodies
against HPV antigens.
Conclusion:We describe an HPV16 qPCR assay to quantify genomic and transcriptomic
expression and correlate this with serum antibody levels against HPV16 oncoproteins.
Understanding DNA/RNA expression, relationship to the antibody response in patients
regarding treatment and outcome offers an attractive tool to improve patient care.
Keywords: oropharyngeal squamous cell carcinoma, human papillomavirus 16, antibody isotype, gene expression,
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Head and neck squamous cell carcinoma (HNSCC) is the sixth
commonest cancer in the western world (1, 2). 25% of all cases of
HNSCC are associated with human papillomavirus (HPV) and 60%
of oropharyngeal squamous cell carcinomas (OPSCC) are HPV-
driven (3, 4). Infection with a high-risk HPV sub-type can result in
the development of OPSCC in individuals irrespective of classical
risk factors such as tobacco use and alcohol consumption (5).
The coding regions of the HPV genome consist of an early
region (E) with six open reading frames (ORF) E1, E2, E4, E5, E6,
E7, and a late region (L) with the ORFs, L1 and L2. The viral
oncoproteins E6 and E7, interact with tumor suppressors p53
and Rb, respectively, inactivating their protective function and
resulting in aberrant cell cycle control (6). As a result of the
functional inactivation of pRb by E7, p16 is upregulated; hence
high expression of p16 is often used as a surrogate diagnostic
marker for HPV16 (7). E2 has important regulatory function in
E6 and E7 gene transcription (8) and viral replication, this
function can be disrupted through integration (9). The viral
oncoprotein E5 can reduce cell surface expression of the HLA
class I, thereby promoting tumor escape from immune control
by CD8+ T cells (10). Nonetheless, patients with HPV-positive
(HPVpos) OPSCC have a better prognosis in comparison to those
with HPV-negative (HPVneg) OPSCC (5). This is most likely
attributable to the patient’s anti-tumor immune response and is
independent of individual treatment regimens (11, 12). The
immunological ‘visibility’ to T cells can be assessed by
counting the number of tumor-infiltrating lymphocytes (TILs),
higher TIL-density correlates with better survival. In contrast,
patients with HPVpos OPSCC but a low TIL-density have a
disease-related survival resembling that of HPV16neg OPSCC
(13). HPV16 antigens can also be recognized by B cells.
Seropositivity to the early genes E1, E2, E4, E6, E7, and L1 has
been described as a serological markers for the presence of
HPV16pos OPSCC (14, 15). HPV16pos OPSCC patients show
increased levels of E6 and E7 antibody in the blood independent
of the viral load (16). Humoral immune responses also link to
outcome: in OPSCC, seropositivity to HPV16 E6 is associated
with a 68% reduction in the risk of death (17). Survival benefit
was also reported in OPSCC patients who were found to be
seropositive to HPV16 E1, E2, or E6 (18).
Systematic analyses of HPV16 genes at the DNA and RNA level,
and their correlation to TIL status and humoral immune responses
have not yet been published; it further remains unclear how often
antibody class switching occurs in HPVpos HNSCC patients.
In this study, we aimed to evaluate the expression of HPV16
genes at a genomic and transcriptomic level, using a qPCR
assay. This helps to understand, which genes of HPV16 genome
are present in the tumor at the DNA level, and which of them
are transcribed in HNSCC. The data were related to the
presence of IgG, IgA and IgM antibodies against the HPV16
E2 and E7 antigens, as determined by ELISA. We used paired
serum samples before and after treatment, to measure IgG and
IgA antibody response to HPV16 E2 and E7 to determine
whether treatment influences the antibody response and how
the removal of the cancer as the source of antigen affectsFrontiers in Oncology | www.frontiersin.org 2antibody levels over time. Additionally, we assessed the TIL
status for those tumors and related this to the HPV16
expression and antibody responses.MATERIAL AND METHODS
Study Ethics
The study given UK Medical Research and Ethics Committee
(MREC 09/H0501/90) and institutional approval at
Southampton University Hospitals NHS Foundation Trust,
Southampton, UK. Written informed consent was obtained
from all patients.
Patient Cohort
Patient samples were collected between 2011 and 2018
(Supplementary Table 1). Perioperative serum samples (n=77)
were selected from patients with p16+ oropharyngeal squamous
cell carcinoma (OPSCC). Stored serum samples were available
for all patients, 73/77 patients had pre-treatment samples, 40/77
patients had post-treatment samples, 36/77 patients had both pre
and post-treatment samples available.
Where available, formalin fixed, paraffin embedded (FFPE)
material (n=27) from the primary tumor were retrieved from
pathology archives. Snap-frozen tissue samples were available for
4/77 patients. TNM was re-staged according to the 8th
edition (AJCC).
DNA, RNA Extraction From FFPE Tissue
and RT-PCR
DNA and RNA were extracted from FFPE tissue in accordance to
the manufacturer’s protocol (Maxwell® RSC DNA FFPE Kit,
AS1450, Maxwell® RSC RNA FFPE Kit, AS1440, Promega,
Southampton, UK). The concentrations of DNA and RNA were
measured using the Nanodrop 2000 (Thermo Scientific, Waltham,
MA, USA). All samples were diluted to a final concentration of 10
ng/µl (DNA), 20 ng/µl (RNA). 2 µl RNA was used for reverse
transcription (20 µl, Superscript III first-strand synthesis system,
Thermo Scientific, Waltham, MA, USA).
qPCR for HPV16
Quantitative polymerase chain reaction (qPCR) was performed
(GoTaq qPCR systems assay, Promega, Southampton, UK) using
1 µl each of DNA (10ng) and 1 µl of cDNA. Samples were loaded
onto 384 well plates in triplicates, read on the Applied
Biosystems 7900HT workstation and analyzed using SDS 2.3
software (Thermo Fisher, Waltham, MA, USA). The qPCR
settings on the workstation were adjusted according to the
manufacturer’s protocol for the GoTaq® assay.
Published primer pairs for all HPV16 genes used are shown in
Table 1 (19–26). Primer pair annealing to the HPV16 genome
NC_001526.4 was confirmed using Primer-BLAST (27, 28).
Primer pairs were confirmed in silico to be specific for HPV16
and to not bind to other high-risk virus genomes. Specificity was
verified using NCBI without detecting any unintended templates
of common human viruses (taxid: 10239). Four E5 primer pairs
were evaluated as we could not generate a PCR product using theJanuary 2021 | Volume 10 | Article 591063
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genomic complementary sequence.
The expression values of the samples (s) were calculated with
the modified DDCt relative expression method (29, 30). The
median Ct(cycle threshold)-value of the gene of interest (GOI)
was normalized against the reference mean (ß-actin) (26). DDCt
relative values were calculated of the positive control (pc) and
subtracted from the total number of cycles to obtain positively
correlation values:
40 − DDCt GOIð Þ = 40 − ð meanCt GOI½ s−meanCt REF½ sð Þ
− meanCt GOI½ pc−meanCt REF½ pc
 Þ
This is a semi-quantitative method; therefore, the relative
values are reported as “amount” or “levels” of DNA and of
RNA expression.
The RNA qPCR was not successful in a subgroup of samples.
We were not able to detect the ß-actin gene, predominantly from
older FFPE pathological blocks (>5 years).
HPV16 Viral Genome Level Analysis
RNA was extracted from snap-frozen tissue of four patients
(Maxwell® RSC simplyRNA Tissue Kit(AS1340), Promega,
Southampton, UK). RNA concentration and quality were
analyzed using the RNA Nano Kit for the 2100 Bioanalyzer
System (Agilent Technologies, Santa Clara, CA, USA). RNA-
sequencing was undertaken by Edinburgh Genomics (University
of Edinburgh, Edinburgh, UK). An automated TruSeq stranded
mRNA-seq library preparation from total RNA and the NovaSeq
sequencing-system was used (100 bp paired-end; 1,750M+1,750M
reads, Illumina, San Diego, CA, USA). This RNA sequencing
dataset was generated in an independent collaboration with
Transgene, and the fact that Transgene funded the RNA
sequencing for four cases of the study, did not influence the study
design, execution, and results interpretation.
The “viral genome level analysis module” of the
bioinformatics pipeline viGen (31) was used to align the
FASTQ files against the human reference genome (hg19), filter
out human RNA-sequences and map un-aligned reads against
the viral reference. Access to the raw and processed data of this
RNA sequencing set is possible via the gene expression omnibus
(GEO accession number: GSE160008).Frontiers in Oncology | www.frontiersin.org 3Immunohistochemistry
p16 IHC on formalin-fixed, paraffin-embedded (FFPE) tumor
tissue was performed as part of the routine diagnostics process
(Supplementary Table 1). Additional IHC was performed on
FFPE tissue using standard protocols for the automated
platforms Dako PT Link for Heat Induced Epitope Retrieval
and Dako Autostainer 48S Link (Agilent, Santa Clara, CA, USA)
with staining of tumor-infiltrating lymphocytes using anti-CD8
antibodies (Anti-Human CD8, Clone C8, 144B, Dako,
concentration: 1:100, Agilent, Santa Clara, CA, USA). An
unsuccessful immunohistochemical approach for HPV16 E2
and E7 was performed with following antibodies [Anti-HPV16
E2, NBP2-53115, NovusBio (no literature), Centennial, CO,
USA; Anti-HPV16 E7, ab20191, Abcam, Cambridge, UK (32);
Anti-HPV16 E7 (716–325), sc-51951, Santa Cruz Biotechnology,
Dallas, TX, USA (33)]. Different concentrations and antigen
retrieval techniques revealed still unspecific staining.
Frequency and density of CD8 positive T cells were
determined as previously described (34, 35). One case was
excluded in the further IHC analysis due to non-specific
IHC staining.
Expression and Purification of HVP16 E2
and E7 Protein
HPV16 E2 and E7 protein were produced in the protein core
facility of the CRUK Experimental Cancer Sciences Center,
Faculty of Medicine, Southampton University.
Control-GST and GST-E2 were expressed as soluble proteins
in bacteria, purified on GSTrap column (17528101, GE
Healthcare, Chicago, IL, USA) and dialyzed in PBS. GST-E7
was expressed as an insoluble protein in bacteria. The protein
was first purified under denaturing conditions in the presence of
urea on a HiTrap Q HP anion exchange column (17115301, GE
Healthcare, Chicago, IL, USA) and dialyzed in buffer without
urea. The dialyzed material was then purified under native
conditions on a HiTrap Q HP anion exchange column prior to
gel filtration in PBS.
The following plasmids were used: p3187 HPV-16 E2 was a
gift from Peter Howley (Addgene plasmid#10846; http://n2t.net/
addgene:10846;RRID : Addgene_10846) (36). pGEX2T E7 was a
gift from Karl Munger (Addgene plasmid#13634; http://n2t.net/TABLE 1 | Primer pairs (custom DNA primer, Sigma-Aldrich) used for qPCR with GoTag qPCR kit (Promega) and SYBR settings including their sequence in 5’-3’
direction, the length of the PCR product, location on the HPV16 genome (NC_001526.4), and the citation to the originate paper.
Gene Forward Primer 5’->3’ Reverse Primer 5’->3’ Size (bp) Location (HPV16 genome) Citation
E1 AGTAGAGCTGCAAAAAGGAGATTA CTGACTACATGGTGTTTCAGTCTC 123 355-454 Nilsson et al. (19)
E2 AACGAAGTATCCTCTCCTGAAATTATTAG CCAAGGCGACGGCTTTG 82 2498-2563 Peitsaro et al. (20)
E4 GACTATCCAGCGACCAAGATCAG CTGAGTCTCTGTGCAACAACTTAGTG 77 2599-2650 Egawa et al. (21)
E5 GCGACGTGAGAGCAACG AGGGGTTTCCGGTGTCTGG na Not found Paolini et al. (22)
E5 GCATCCACAACATTACTGGCG GTAGACACAGACAAAAGCAGCGG 95 3004-3076 Um et al. (23)
E5 CTTTGCTTTTGTGTGCTTTTGTGTG AAAGCGTGCATGTGTATGTATTAAA 192 3034-3201 Sahab et al. (24)
E5 ATGACAAATCTTGATACTGCA AATGATGTGTATGTAGACACAG 125 2986-3089 Campo et al. (25)
E6 GAGAACTGCAATGTTTCAGGACC TGTATAGTTGTTTGCAGCTCTGTGC 81 7136-7192 Peitsaro et al. (20)
E7 AAGTGTGACTCTACGCTTCGGTT GCCCATTAACAGGTCTTCCAAA 78 7781-7837 Wang-Johanning et al. (26)
L1 TTAGGTGTGGGCATTAGTGG TCCCCTATAGGTGGTTTGCA 164 5111-5255 Nilsson et al. (19)
L2 GACCCTGCTTTTGTAACCACTC ATGCTGGCCTATGTAAAGCAAC 166 4087-4231 Nilsson et al. (19)
ß-actin TCACCCACACTGTGCCCATCTACGA CAGCGGAACCGCTCATTGCCAATGG 295 n.a. Wang-Johanning et al. (26)January 2021 | Volume 10 | Article 591063
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protein expression and purification methods failed, as non-
reliable ELISA results were detected.
ELISA
A standard ELISA was performed in triplicates including a
standard curve and negative control. Plates were coated with
GST HPV16 E2 and E7 with a working concentration of 2µg/mL
at 4°C overnight. Total IgG (goat anti-human (Fc), HRP, A0179,
Sigma, St. Louis, MO, USA), IgA (Goat anti-human IgA (Heavy
chain), HRP, PA1-74395), and IgM (Goat anti-human IgM
(Heavy chain), HRP, A18835, Thermo Scientific, Waltham,
MA, USA) were used as secondary antibodies. The Multiskan
FC Microplate Photometer was used to analyze the plates, and
OD values were exported using the SkanIt software (Thermo
Scientific, Waltham, MA, USA).
A standard curve was generated by seven steps of doubling
dilutions starting at a concentration of 1:100 using a pool of
positive sera. Antibody titers were measured in arbitrary units
(AU) using this standard curve. The negative control serum pool
was used to set the positive cut-off point (mean+1.645
standard deviations).
Analysis and Statistics
The statistical evaluations were undertaken and graphed using
Microsoft Excel (version 16.33) and GraphPad Prism (version
8.4.2). Nonparametric unpaired (Mann-Whitney test) or paired
tests (Wilcoxon signed-rank test) were used. Correlations are
reported using the nonparametric Spearman’s correlation
coefficient. An r-value <0.3 was deemed as very weak, 0.3–<0.5
as weak, 0.5–0.7 moderate and >0.7 as strong (38). The survival
analysis was performed using the Kaplan-Meier estimator and a
Mantel-Cox log-rank test to compare survival curves. P-values
less than 0.05 was considered statistically significant.RESULTS
Patient Summary
Our clinical cohort of 77 patients included only p16+
oropharyngeal tumors (patient characteristics shown in Table
2). Most of the tumors were histologically non-keratinizing
squamous cell carcinoma (58/77, 75%). Higher tumor stage
was associated with poor survival (p=0.0133, Figure S1). The
patient’s treatment is summarized in Table 2. Three patients had
after primary CRT/RT a surgical salvage (only preoperative
serum samples were evaluated). The median follow-up time
was 4 years and 5 months (Overall survival: 2-year: 94%, 5-
year: 85.3%). No significant difference in survival according to
gender, age, tumor site or nodal status was found.
Analysis of HPV16 DNA and RNA
The HPV16 genes E1, E2, E4, E5, E6, E7, L1, and L2, were
assessed using qPCR assays on DNA and cDNA from 27 p16+
OPSCC patients. We could not detect the complementary
sequence in the HPV16 genome for the primer pair publishedFrontiers in Oncology | www.frontiersin.org 4by Paolini et al. (22) using primer-BLAST (28). This primer pair
was not used in further analyses. Additional three published
E5 primer sets were evaluated (Supplementary Table 1).
A concordant correlation of E5 DNA with the other HPV16
genes was observed using these primer pairs (Figure S2). For
further analysis we chose to proceed with the E5 primer pair
which had previously been used in HNSCC (Um et al.) (23).
The quantity of DNA identified for the early and late genes is
shown in Figure 1A, expressed as 40-DDCt values and ordered
by the amount of DNA of the oncogenic E6. In three patients
(Case 25, 26, 27) no DNA was detected for any HPV16 gene;
these cases were excluded from further analysis and classified as
false positive (HPV-status) p16 IHC results.
In the remaining 24 samples, HPV16 DNA was present (40-
DDCT range: 22.96-40) (Figure 1A). 40-DDCT was highly
consistent for E6, E1, E2, E4, L1, and L2 within any individual
patient. By contrast, the 40-DDCT detection thresholds of DNA
for E7 and E5 genes were less correlated with the other HPV16
genes (in particular case 3). No E5 DNA was detected in case 24
(Figure 1A), despite this patient having the highest 40-DDCT
values for the other HPV16 genes.
The correlation matrix in Figure 1B shows the Spearman’s
correlation coefficients (r-values) and the respective p-values.
The analysis showed a high correlation of E6 DNA to that of the
other genes (strongest for E1 and E6, r=0.97, p<0.0001). In
contrast, the amounts of E7 DNA were less correlated with
other HPV genes, especially with E5 DNA (r=0.22, not
significant) (Figure 1B). This is consistent with the visual
impression in Figure 1A. E7 and E5 were only modestly
correlated with the 40-DDCT values from other HPV16 genes;
the r-values ranged from 0.45 to 0.66 (p<0.05, Figure 1B). A
highly significant correlation (r>0.85, p<0.001) was observed forTABLE 2 | Summary of the patient characteristics.
Descriptive Statistics n= Percentage
Patients All 77 100%
Gender Male 67 87%
Female 10 13%
Age Median (years) 56
Range (years) 35-79
Tumor Oropharynx 77 100%
Base of Tongue 28 36%
Tonsil 49 64%








Treatment Surgery +/- adj. CRT/RT 23 30%
CRT/RT 51 66%
CRT/RT + Surgery 3 4%January 2021 | Volume 10 | Article 591063






FIGURE 1 | Graphs showing the qPCR data of 27 p16+ HNSCC patients analyzed. (A) Bar graph displaying 40-DDCT values of DNA for all HPV16 genes of all
patients including the blank and negative control (p16 and HPV16 negative non oropharyngeal HNSCC) ordered by the amount of E6 DNA. HPV16neg false p16
positive cases are marked with a red dot. (B) The correlation matrix on the left shows the Spearman’s correlation coefficients (r) of each HPV16 gene DNA quantity
compared to each other. The right matrix displays the corresponding significance levels. (C) Scatter plot displaying individual correlations between the DNA levels of
the oncogenic genes E5, E6, and E7. (D) Bar graph displaying 40-DDCT values of RNA for all HPV16 genes of all patients including the blank and negative control
(p16 and HPV16 negative non oropharyngeal HNSCC) ordered by the amount of E6 DNA (A). HPV16neg false p16 positive cases are marked with a red dot and not
analyzable cases are not labelled on the x-axis and are marked with a cross. (E) The correlation matrix on the left shows the Spearman’s correlation coefficients (r) of
each HPV16 gene RNA expression compared to each other. The right matrix displays the corresponding significance levels. (F) Scatter plot displaying individual
correlations between the RNA expression of the oncogenic genes E5, E6, and E7.Frontiers in Oncology | www.frontiersin.org January 2021 | Volume 10 | Article 5910635
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each other and the late genes L1 and L2 (Figure 1B). Per-patient
correlations between the DNA levels of the oncogenic genes E5,
E6, and E7 are displayed in a scatterplot in Figure 1C with an
r-value of 0.45 for E6 vs E7.
To study transcription of the HPV16 genes, we performed
qPCR analysis on cDNA. In seven cases (5, 18, 21, 22, 24, 26,
and 27) the quality and amount of RNA was too low to detect
the housekeeping gene, b-actin and these are marked with a
cross on Figure 1D. As expected in case 25, (previously
identified as HPV16 negative) we did not detect HPV16 RNA.
Overall, a total of 19 samples yielded product in the qPCR RNA
expression analysis and we detected 40-DDCt values ranging
from 28.6–40.
RNA expression of all HPV16 genes were found in 7/19
(37%) patients. In five patients we detected all early genes but
only one late gene (26%); in two cases we found all early genes
but no late genes (11%) (Figure 1D). In case 4 we found RNA
for all early genes except E5; and in case 20 we found no E7
RNA despite the detection of DNA. Overall, expression of RNA
for late genes was detected in 11/19 cases (58%) for L1, 10/19
cases (53%) for L2, and seven cases had a co-expression of L1
and L2 (37%).
Using Spearman’s correlation coefficient to assess HPV16
genes (Figure 1E), E6 transcripts were highly correlated with
those for E1 (r=0.85, p<0.0001) and E7 (r=0.7, p<0.0001), while
E7 transcripts were highly correlated with those for E2/L1
(r=0.74, p<0.0001). Poor correlation was shown between E5/E6
(r=0.25, not significant), E5/E7 (r=0.47, p<0.05) and E5/E1
transcripts (r=0.18, not significant). However, E5 RNA was
highly correlated with E2 (r=0.66, p<0.001) and E4 RNA
(r=0.63, p<0.001). Figure 1E also shows the strongest
correlation between the transcripts for E2/E4 (r=0.97).
Per-patient correlations between the RNA expression for the
oncogenic genes E5, E6 and E7 are shown in Figure 1F. For both
E6/E7 and E5/E7 the correlation between RNA expression of
those oncogenes has a moderate (r=0.47) and high (r=0.70)
correlation value respectively. Whereas the E5/E6 correlation
was low and not statistically significant.
We quantified the HPV16 viral transcripts in 4 cases (15, 16,
23, and 27) using RNA-sequencing and compared this to the
qPCR results. The 40-DDCt values assessed by qPCR for DNA
and RNA are displayed together with the HPV16 genome
alignment using RNA-sequencing data in Figure 2. Consistent
with data from qPCR, case 27 did not have any expressed HPV16
genes detected by RNA-sequencing either (previously identified
as HPV16neg). The other three cases showed high amount for all
HPV16 genes and RNA transcripts assessed by qPCR as well as
by using RNA-sequencing alignment.
Correlation of IgG and IgA Antibodies
to HPV16 E2 and E7
Total IgM, IgG, and IgA antibody responses to E2, E6, and E7
antigens were evaluated using ELISA. E6 protein showed
unreliable and inconsistent results, most likely due to
problems in protein folding in the protein expression systemFrontiers in Oncology | www.frontiersin.org 6(data not shown). 3/73 pre-treatment samples (4%) contained
strongly detectable IgM antibodies against E2 and E7
simultaneously, perhaps reflecting recent re-exposure of
HPV16. Interestingly, the HPVneg case 25 had low levels of
circulating E2 IgG (AU=0.2) and E7 IgA (AU=0.8), likely
reflecting an unrelated, cleared infection with HPV16. The
other two HPVneg cases (26 and 27), had no detectable
antibodies to E2 and E7.
Of the remaining 70 pre-treatment serum samples, 46 were
positive for E2 IgG, 56 for E7 IgG, 28 for E2 IgA, and 63 for E7
IgA. Thirty-nine cases were positive for E2 and E7 IgG, while 24
had positive ELISA results for E2 and E7 IgA. Positive results for
all different antigen-antibody combinations were found in 20
cases. We assessed the relationship between IgA and IgG
antibody levels (including the post-treatment samples; Figure
S3). The antibody levels were correlated with weak to high
correlation values.
Antibody levels were not related to the location of the primary
tumor (Figure 3A), nodal status or primary treatment strategy
(not shown). Figure 3B shows that T2 and T3 tumors appear to
have higher levels of E2 and E7 IgG, and E7 IgA antibodies, but
these differences did not reach significance.
IgA Antibody Levels Are Increased Early
After Treatment
We compared pairs (n=32) with an interval of ≤6 months or >6
months between samples to understand the post-treatment
kinetics. IgA antibody levels against E2 and E7 increased
within the first 6 months post-treatment (p=0.0232 and
p=0.034, respectively), while this was not seen for IgG (Figures
3C, D).
We compared all baseline samples (n=67) against all post-
treatment samples (n=36). IgG and IgA antibody levels remained
stable ≤6 months after treatment. A significant decrease in IgG
antibody levels >6 months after treatment was seen (Figures 3C,
D). This was also the case for anti-E7 IgA antibodies, but it did
not reach significance.
Patients With High Levels of Anti-E2 IgG
Have a Better Overall Survival
Using ELISA and follow-up data from 77 patients, we performed
Kaplan-Meier survival analysis. When the cohort was divided
into E2 IgG high vs E2 IgG low, according to the median AU
values, patients with high E2 IgG antibody levels showed a
significantly longer survival than those with low levels
(p=0.0321). Exclusion of HPVneg qPCR cases did not change
the survival analysis, on the contrary, it increased the significance
slightly to p=0.0311 (Figure 3E). A similar trend was shown for
E7 IgG, but we did not detect a link between IgA antibody levels
and outcome (Figure 3E).
High HPV16 DNA Levels and RNA
Expression for E7 Are Correlated With
Antibody Level
AU values were plotted against the amount of E2 and E7 DNA
and RNA after classifying them into a low value (40-DDCt <30)January 2021 | Volume 10 | Article 591063
von Witzleben et al. HPV16 Gene Expression and Seropositivityor high value (40-DDCt ≥30) group (DNA: Figure 4A, RNA:
Figure 4B). The cut-off was based on the rounded average
40-DDCt values of 30.42 on DNA level. Detection of more E2
DNA or transcripts did not relate to higher serum levels of anti-
E2 IgG or IgA antibody. However, E7 DNA and RNA transcripts
were associated with a higher AU value for anti-E7 IgG and IgA,
although the effect was not statistically significant, most likely
due to low case numbers. Grouping the ELISA results showed
that high amounts of DNA were significantly correlated with
high AU values (p=0.035).Frontiers in Oncology | www.frontiersin.org 7TIL Status Has an Influence on Antibody
Levels Against HPV16 E2 and E7
The TIL status of patients was determined using IHC staining
specific for CD8+ cells and categorized into high, moderate and
low as previously published (13). In the HPV16pos qPCR cohort
(n=24) 15 patients had a high TIL count for CD8. The rest
showed a moderate or low TIL count (Figures 4C, D).
AU were plotted in the three TIL categories according to the
number of CD8+ cells (Figure 4C). Due to the small numbers in
the low expression group we combined all ELISA data (E2 IgG,A
B
C
FIGURE 2 | Bar graphs showing the qPCR and RNA-sequencing data of four selected patients (15, 16, 23, 27). (A) Bar graph displaying 40-DDCT values of DNA for all
HPV16 genes of those patients. The HPV16neg (false p16 positive case 27) is marked with a grey dot. (B) Bar graph showing the corresponding 40-DDCT values of RNA
for the respective patients (C) Bar graph showing the log2(n+1) normalized counts for the HPV16 genome using RNA-sequencing data of respective patients.January 2021 | Volume 10 | Article 591063
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FIGURE 3 | ELISA results reported in arbitrary units (AU) from samples taken at baseline before treatment. (A) Bar graph showing AU values for the tumor site base
of tongue (BOT) and tonsil for the antibody classes IgG and IgA. (B) Bar graph displaying AU values depending on the tumor size [small tumor size (T1) and
advanced tumor status (T4)]. (C) Graph showing ELISA AU values of pre- and post-treatment samples for IgG. The top two figures show the paired E2 IgG data
grouped by time in months when the second sample was taken after completion of treatment, less than 6 months (<6 months) and more than 6 months (>6
months). The bottom graphs display all pre-treatment and post-treatment samples and are plotted separated by their second sample date. Significance levels are
shown for E2 IgG and E7 IgG (p<0.05). (D) Graphs showing the ELISA results for IgA with a statistically significant increase in the group with sample <6 months after
treatment end (E2: p=0.0232, E7: p=0.0384). (ns, not significant; *: p≤0.05, **: p≤0.01). (E) Kaplan-Meier graph of overall survival of 74 patients (n=3 qPCR HPV16
negative excluded) grouping in IgG E2 low (n=33) and IgG E2 high (n=41) using median antibody values. The IgG E2 high group shows a significant better overall
survival than the low AU value group (OS after 5 years: 95% vs 74%, p=0.0.311). E7 IgG shows a not statistically significant difference of the overall survival.Frontiers in Oncology | www.frontiersin.org January 2021 | Volume 10 | Article 5910638




FIGURE 4 | Bar plots showing the comparison of antibody levels with E2 and E7 expression levels on DNA, RNA and with the TIL status (A) High DNA expression
level of E7 is accompanied with statistically significant higher AU values (p=0.0245) of E7 IgG in the serum (B) the RNA expression level and ELISA antibody units are
congruent to the DNA results, but not statistically significant (p=0.07). (C) Patients with high or moderate TIL status assessed by CD8 have higher AU values in the
serum for E2 and E7 IgG than patients with TILlow tumors. The same trend is seen for E2 and E7 IgA. Combining all ELISA data to a summarized seropositivity the
TILhigh HNSCC show significantly higher AU values than the low. (**: p≤0.01). (D) Table showing the case numbers and their TIL status for CD103 and CD8.Frontiers in Oncology | www.frontiersin.org January 2021 | Volume 10 | Article 5910639
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seropositivity with the TIL status. Significant more circulating
antibodies in TILhigh tumors were found (p=0.0097).DISCUSSION
Several diagnostic approaches for HPV16 detection are
described. The assessments include HPV-PCR, HPV-in situ
hybridization (ISH) and the hybrid-capture HPV DNA Test
which can be used to detect a whole group of high-risk and low-
risk HPV types (39). Hitherto, only few methods for the
detection of HPV16 in FFPE material have been published
(40). Systematic assessment of the HPV16 genome, quantifying
all genes separately, had not yet been undertaken. The primer
pairs we used in the qPCR assay for HPV16 detection were
rigorously tested to be specific for each HPV16 gene, without
cross reactivities to other high-risk HPV types, or other human
viruses. The assay specificity was also supported by using the
viGen bioinformatic pipeline (31) to detect HPV16 genes,
mapping the RNA-sequencing data onto HPV16 genome.
This separate analysis using different starting material
revealed the same findings and confirms the validity of our
qPCR assay.
Evaluation of all HPV16 genes in OPSCC with qPCR revealed
highly correlated amounts of HPV16 gene DNA with the lowest
values for E5 and E7. Intriguingly, we could detect all HPV16
genes in most cases. E5 expression displayed the lowest
correlation with other HPV16 genes and was absent in case 24.
E5 is composed of 83 amino acids, making it the smallest of all
HPV16 genes. E5 has been shown to be necessary for early cancer
development and can be lost during the course of cancer
development (41). Our case is likely an example of this
process. We identified 3 HPVneg cases in our cohort (n=27),
which expressed high levels of p16 protein. This is approximately
11% and is in the lower range of published percentages of 15%–
20% for p16+ but HPV-ISHneg HNSCC (7).
The 40-DDCT values for DNA differ from those identified for
RNA expression, reflecting variable transcriptional activity
between cases. The late genes L1 and L2 are both transcribed
from the late promotor and are only expressed in the surface of
the stratified squamous epithelium, while in the basal cells only
early genes are transcribed (42). The assembly and dissemination
of HPV16 from the superficial epithelial cells happens after late
antigen expression. However, in the case of tumor formation,
viral assembly is not critical once transformation has occurred
and hence, the late genes are likely redundant. Intriguingly, the
late antigens are still transcribed into RNA in 58% of cases for L1,
53% for L2 and 37% expressed both. This finding underpins
the possibility of complete viral reassembly in more than one
third of cases, supporting the risk of viral transmission between
partners after the cancer has been established (43). If true, this
has important social implications for the patient and their
partner(s). This question should be evaluated formally in
prospective work to assess whether a prophylactic vaccine may
be indicated for partners and patients.Frontiers in Oncology | www.frontiersin.org 10We describe two cases where E7 DNA is detected, but not
transcribed. Both oncogenes E5 and E6 however are transcribed
in those cases. It is not clear if E7 was expressed during cancer
initiation, and then lost during cancer growth, or if there is an
immunological mechanism (one case was TILhigh, the other
TILlow). In contrast to published data, we could detect E2 RNA
at the same time as RNA for E6 and E7 (9) suggesting that E2
does not necessarily exert inhibitory transcriptional control over
E6/E7 expression (8).
It has been reported that patients with HPV16pos OPSCC show
increased levels of E6 and E7 antibodies in the blood, independent
of the viral load (16). However, we find a correlation between E7
DNA and RNA expression and higher serum levels of IgG and IgA
antibodies against E7, but not E2: thus, individual genes of HPV16
appear to be differentially expressed, transcribed and could be
differentially immunogenic. Therefore, a detailed analysis on a
gene by gene basis is important for being able to interpret
immunological data.
E2 has previously been reported to be associated with a
greater cytotoxic T lymphocyte response compared to E7 (44).
We did not directly assess T cell reactivity in our cases; the
humoral responses we observe however raise the possibility that
T helper cells are less activated in response to E2 than E7, and
therefore lead to less B cell activation and antibody production.
The relationship between HPV16 gene expression and
antigenicity requires further investigation. This would also
have important implications for vaccine development.
The presence of viral antigen leads to the activation of
immune responses aimed at clearing the infection. This
clearance requires both T and B cell activation. T cells
activated against HPV antigens are able to recognize the
intracellular virus through presentation of viral peptides in
MHC molecules, and this has been shown by the presence of
virus-specific T cells in HPVpos HNSCC (45). These T helper
cells activate B cells to produce specific antibodies which can
then be detected in the serum of patients e.g. by ELISA. ELISA is
a rapid and inexpensive assay which can give additional
information about the patients’ prognosis beforehand and
could be a useful additional diagnostic tool.
Antibodies directed against HPV early antigens have been
proposed as a prognostic biomarker before and after removal of
the tumor (46). If treatment is successful it would remove the
source of HPV antigen, limiting B cell responses. Therefore,
following effective CRT or complete surgical resection of all
disease, a significant decrease or loss of antibodies over time is
expected. Continued detection of antibodies may indicate either
residual tumor (post-CRT) or distant metastasis (post-complete
surgical resection). 15%–20% of HPVpos patients die from
residual or recurrent disease within 2-years and a simple blood
based biomarker would be clinically relevant (47). While pre-
and post-surgery levels of E6 antibody have been described as a
prognostic indicator of recurrence (48), pre and post-treatment
levels of antibody to E7 appear to serve as a biomarker. In our
study, the pre- and post-treatment antigen levels were different
in the two groups sampled at different times (<6/>6 months).
However, we could not assess the relevance of antibodies as aJanuary 2021 | Volume 10 | Article 591063
von Witzleben et al. HPV16 Gene Expression and Seropositivitybiomarker of recurrence in our cohort as no recurrences
occurred during the period of sample collection.
We saw stable antibody levels for E2 IgG before treatment and in
serum samples taken in the first 6 months after treatment, while
there was a slight increase in anti-E7 IgG; after that timepoint
antibody levels decreased. This finding is consistent with the
published data by Fakhry et al. (48). For IgA, in the first 6
months after surgery, we saw increasing antibody levels in the
blood, but again after 6 months, these levels decreased. Therefore,
even after the tumor is completely removed, antibodies persist in the
blood. As the half-life of immunoglobulins is much less than 6
months, these findings must mean that HPV16-reactive B cells/
Plasma cells may persist in lymphatic structures, for example the
bone marrow. Nonetheless, these B cells must be relatively short
lived as, following tumor removal, we find that after 6 months
antibody levels decline. As expected, the kinetics for E6 and E7
DNA are different and decrease rapidly after treatment in oral rinse
samples in contrast to the antibody responses (49), demonstrating
that both tests offer different biological insights in to the success
of treatment.
Consistent with published data (17, 50) we confirmed better
survival for OPSCC patients with IgG responses to the E2 gene it
is thought that the antigenic determinant is located at the N
terminal region of E2 (18). A fascinating new observation from
our study is that the presence of IgA antibodies does not appear
to link to survival benefit. This is intriguing, as IgA responses
have been accused of dismantling adaptive T cell responses in
human liver cancer (51). Formal study of the biological function
of IgA+ B cells and plasma cells is needed to understand the
underpinning biology. Consistent with the published data, there
was no significant survival benefit seen for E7 antibody
seropositivity, although a trend emerged after longer follow-up.
Generally, patients with HPVpos OPSCC have a better
outcome than HPVneg patients, but those HPVpos with low TIL
status have the same poor outcome as HPVneg OPSCC (13).
Patients with immune-cold tumors (TILlow) had less antibody
production, while immune-hot tumors (TILhigh) were associated
with greater antibody production. Our data is consistent with the
observation that B cells and T cells are abundant in the same
cancers (52), the antibody levels demonstrate the functional link
between these cell populations, most likely anatomically located
together in tertiary lymphatic structures in the cancer
microenvironment. Importantly, the circulating antibody levels
may be a potential biomarker to stratify patients in clinical trials
evaluating immunotherapies.
Caveats for generalizing our data include the small size of our
qPCR cohort, as some samples were too low-quality for further
analysis. This might also be a limitation in using FFPE material:
RNA is less stable than DNA and consistent with this is that
technical failures occurred in the older FFPE blocks.
In our serum sample cohort, the selection criteria were
based on p16, as the commonly available surrogate marker for
HPV-driven disease. This may have biased case choice and going
forward, we would use the qPCR for DNA in combination
with p16 IHC as the more robust tool for identifying
HPV16pos tumors.Frontiers in Oncology | www.frontiersin.org 11The ELISA assay had initially been planned to include antibodies
against E2, E6 and E7. However, we did not successfully express E6
protein. Nevertheless, including E6 and E5 in future research could
unfold additional insights in antibody responses to those oncogenic
HPV16 antigens. ELISA findings have to be confirmed
prospectively in a larger HPVpos OPSCC cohort with
standardized and consecutive serum sample collection. This
would validate our results and improve the understanding of
HPV16 expression at genomic and transcriptomic levels, as well
as antibody responses and their clinical impact.DATA AVAILABILITY STATEMENT
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